soul trial oral semaglutide cardiovascular outcomes 2024 Cuts Risk by 14% in Oral Semaglutide Cuts Cardiovascular Risk
Description
Semaglutide activates GLP-1 receptors throughout the digestive tract, potentially influencing gut motility and inflammation
Even the most advanced therapy wont replace those
GLP-1 drugs like Wegovy and Zepbound are highly effective but costly
GLP-1 agonists reduced lung fibrosis in mice after COVID-19 infection
The one in eight Americans currently using GLP-1s, like Ozempic, are considering pausing their drugs for the holidays
Semaglutide injection site reactions range from mild redness to localized swelling and typically resolve within hours to days
